In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EnteroMedics' Maestro "on track" despite FDA questions

This article was originally published in Clinica

Executive Summary

EnteroMedics has been hit by more potential problems with its Maestro neuromodulation-based weight-loss device – this time in the shape of questions from the US FDA in response to the firm’s premarket approval (PMA) application. The company’s share price fell 12% to a low of $1.07 during trading on 24 September, when the news was released, but ended up recovering to close down 2% at $1.18.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT100891

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel